AI in Alzheimer's and Dementia Detection

Dementia describes symptoms that affect memory, reasoning, or daily function; Alzheimer’s disease is one possible cause. Evaluation can involve history, examination, cognitive testing, laboratory work, and sometimes imaging or biomarkers. AI methods study patterns in MRI, PET, speech, records, or test results. A model trained to distinguish research groups may not diagnose an individual in another clinic. The National Institute on Aging explains that biomarkers can help identify Alzheimer’s-related changes, but their clinical role depends on the test and setting. A biomarker does not replace assessment of symptoms, other causes, and functional change. Blood-based tests are an evolving area; evidence for one assay should not be generalized to all tests. AI can process complex data or prioritize review, but accuracy claims require independent validation in the intended population. For a clinical tool, teams should define the decision it supports, verify compatible scans or assays, and compare results with suitable reference standards. They should assess false positives and false negatives, check performance across age and demographic groups, and explain uncertainty. A model score must not delay evaluation of sudden confusion or other urgent symptoms. Clinicians remain responsible for interpretation and care planning, and families should be included when the patient wishes. Teams also need a plan for communicating uncertain or discordant results, especially when a test raises concern but symptoms do not fit. Consider access to confirmatory testing before introducing automated triage.